nach oben

Erschienen in:

Open Access 12.07.2023 | Original Research Article

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers

verfasst von: Samira Ait Abdellah, Véronique Raverot, Caroline Gal, Isabelle Guinobert, Valérie Bardot, Claude Blondeau, Bruno Claustrat

Erschienen in: Drugs in R&D | Ausgabe 3/2023

Abstract

Background

The benefit of exogenous melatonin is based on its bioavailability, which depends on the galenic form, the route of administration, the dosage, and the individual absorption and rate of hepatic metabolism.

Objective

The objective of this study is to investigate the bioavailability of melatonin after administration of an oral prolonged-release tablet (PR form) and an immediate-release sublingual spray (IR form). The main metabolite of melatonin, 6-sulfatoxymelatonin (6-SMT), was also measured, which has not been done in previous studies. Its determination is important as an index of the hepatic transformation of melatonin.

Methods

In this single-center, open-label, randomized, crossover study, 14 healthy male volunteers received one tablet of the PR form (1.9 mg melatonin) or two sprays of the IR form (1 mg melatonin) during two visits separated by a washout period. Blood samples were collected over 7 and 9 h for the IR and PR form, respectively, to determine the main pharmacokinetic parameters.

Results

The observed kinetics were consistent with those expected for immediate and prolonged-release forms. Pulverization of the spray resulted in an early, high plasma melatonin peak (C_max: 2332 ± 950 pg/mL; T_max: 23.3 ± 6.5 min), whereas tablet intake produced a lower peak (C_max: 1151 ± 565 pg/mL; T_max: 64.2 ± 44.2 min; p < 0.001 for comparison of C_max and T_max) followed by a plasma melatonin plateau and a more prolonged decay over time. Plasma melatonin/6-SMT AUC_0–540/420 ratio was 0.09 for the PR form and 0.16 for the IR form. Both galenic forms were well tolerated.

Conclusions

The results suggest that the galenic forms containing melatonin assessed in this study are suitable for the treatment of certain sleep disorders such as sleep onset delay and transient nocturnal awakenings for the IR form and insomnia for the PR form.

Trial Registry

Registration number: NCT04574141.

Key Points

We assessed melatonin bioavailability after administration of a prolonged-release tablet and an immediate-release sublingual spray.

The observed kinetics were consistent with those expected for immediate- and prolonged-release forms.

Plasma peak concentration of melatonin after ingestion of the tablet was half that of the spray, this peak being reached three times later with the tablet. Up to 6 h after intake, the tablet released melatonin at a concentration with physiological meaning (i.e., more than 100 pg/mL).

1 Introduction

Melatonin is a hormone secreted by the pineal gland that displays a very marked nycthemeral rhythm that is entrained to the light–dark cycle [1]. The secretion spreads over 8–10 h, with a maximum around 3–4 a.m. The blood melatonin profile can be considered as the result of a hormone infusion reinforced by episodes of secretion. Melatonin displays a short blood half-life and a fast turnover and undergoes high first-pass hepatic metabolism. More than 80% of endogenous melatonin is excreted in the urine as 6-sulfatoxymelatonin (6-SMT) [1, 2], which can also be detected in plasma [3].

Exogenous melatonin is now well recognized for its potential in treating sleep problems since melatonin supplementation has been shown to improve sleep onset latency, duration, and quality in children, adults, and the elderly [4‐9]. The European health authorities have issued a favorable opinion for the claim that “melatonin contributes to the reduction of time taken to fall asleep” that can be used only for food supplements containing 1 mg of melatonin per quantified portion [10]. Recent meta-analyses of randomized controlled trials have confirmed the beneficial effects of exogenous melatonin on sleep onset latency [11] and sleep quality [12]. Melatonin is well tolerated with no association with impairment of psychomotor functions, memory recall, and driving skills [13]. It is also devoid of side-effects such as hangover, nocturnal confusion, negative effects on cognitive performance, and dependency. Melatonin can be considered as an alternative that is better tolerated and more suitable for some populations compared with certain highly prescribed molecules such as benzodiazepines, whose chronic use is a major public health problem [14, 15].

Numerous galenic formulations that attempt to optimize or adapt the bioavailability of melatonin have been developed. As melatonin bioavailability depends on the galenic form, the route of administration, the dosage, and the individual absorption and rate of hepatic metabolism, pharmacokinetic studies are needed to investigate the bioavailability of melatonin for each new galenic formulation brought to the market [13, 16, 17].

Here, we conducted a study to document the bioavailability of melatonin after administration of an oral prolonged-release tablet and an immediate-release sublingual spray. Both preparations are of major interest. The prolonged-release tablet was developed to mimic the plateau observed with endogenous melatonin secretion, whereas the sublingual spray was designed to provide an early melatonin peak, and to limit first-pass hepatic metabolism, since vascularization is highly developed under the tongue. We also measured the metabolite 6-SMT, which has not been measured in previously published studies with such melatonin formulations [1, 18, 19]. Its determination is important as an index of the hepatic transformation of melatonin.

2 Materials and Methods

2.1 Study Products

The prolonged-release tablet (Chronobiane LP) and the immediate-release sublingual spray (Chronobiane Immédiat, Chronobiane Instántaneo) evaluated in this study are dietary supplements marketed by PiLeJe Laboratoire. Both products have been previously validated by in vitro studies. The prolonged-release tablet form (PR form) contains 1.9 mg of melatonin, in accordance with the French regulation that allows the marketing of food supplements providing less than 2 mg of melatonin per day. The immediate-release spray form (IR form) consists of a device that ensures the administration of 1 mg melatonin for two sublingual sprays. Since it is expected that a spray will immediately result in a high blood melatonin level, the dosage is limited to 1 mg.

2.2 Study Design and Ethics Statement

This was a single-center, open-label, randomized, crossover bioavailability study that was conducted in accordance with Good Clinical Practices and received a favorable opinion from a Personal Protection Committee (CPP Sud-Est I, CHU Saint Etienne, France) before its implementation on 10 July 2020. The registration number on the ClinicalTrials.gov site is NCT04574141.

2.3 Volunteers

Men between 18 and 45 years of age, over 70 kg, with a body mass index (BMI) between 18.5 and 24.9 kg/m², in good general health (i.e., without any chronic pathology and not taking any medication at the time of inclusion and/or on a long-term basis), able and willing to participate in the research by complying with the protocol, having freely signed the consent form and affiliated to a social security system were eligible to participate in the study. They also had to present none of the following non-inclusion criteria:

Smoking, drug consumption, drinking more than two glasses of alcohol per day;
Taking melatonin or a product containing it during the 48 h preceding the study visit;
Known organic or functional abnormality of the urinary tree;
Medical conditions that would imply a modification of the melatonin metabolism including drug intake (fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, carbamazepine and rifampin, analgesics); known liver abnormality or detected during the screening visit and judged as clinically significant by the investigator; or known autoimmune disease;
Assessed as “somewhat” or “completely” an evening person [20]; having sleep disorders (score < 7 on a 10-point visual analog scale [VAS]); working on atypical schedules (night work, shifts). Evening-type subjects (scoring less than 31 on the Horne questionnaire) were excluded from the study since they usually display residual morning melatonin secretion;
Having a diagnosis of migraine according to the criteria of the International Headache Society [21];
Known hypertension (> 140/90), thyroid dysfunction, hyperglycemia, or anemia deemed clinically significant by the investigator;
Known organic or psychological abnormality (including history of severe depression) that may bias the study results in the judgment of the investigator.

The study was conducted in men since there is a potential gender difference in melatonin pharmacokinetics. In addition, endogenous or exogenous sexual steroids may influence melatonin secretion in women (related to follicular or luteal phase, contraceptive pill, menopausal status, etc.), which could add heterogeneity to the results.

All volunteers complying with the inclusion criteria and meeting none of the non-inclusion criteria received complete information about the study and gave their written consent. Volunteers were free to terminate their participation in the study at any time.

2.4 Study Endpoints

As measurement periods should be long enough not to underestimate the bioavailability of melatonin across different galenic formulations and studies should attempt to provide pharmacokinetic analyses of melatonin metabolites including 6-SMT [17], the primary endpoint was the evolution of plasma melatonin concentration over 540 min (9 h) after taking the PR form and over 420 min (7 h) after taking the IR form. The area under the curve (AUC), C_max, T_max, and T_1/2 values were calculated. Secondary endpoints were the evolution of plasma 6-SMT concentration (AUC, C_max, T_max, and T_1/2) and tolerance (adverse events collected during and after each kinetics).

2.5 Study Flow and Data Collection

The study comprised three visits, a screening visit (V1) and two study visits (V2 and V3), separated by a washout period of at least 5 days. A maximum of 45 days following V1 was allowed for the completion of the two kinetics (Fig. 1A).

At V1, sociodemographic data, cardiovascular parameters (blood pressure and heart rate), and general medical history were recorded by the investigator. Blood samples (2 × 5 mL) were collected for standard assays (blood count and platelets, glucose, creatinine, urea, liver tests, thyroid stimulating hormone (TSH), and C-reactive protein). If the results were within normal ranges, the volunteer was included, and randomization performed to determine the order of allocation of study products for each study visit.

Foods rich in melatonin or tryptophan (a precursor of melatonin) should be restricted for 2 days before and during each study visit. In addition, volunteers were instructed not to engage in prolonged, high-intensity physical exercise during the 24 h preceding each study visit.

On the day of the study visits (V2 and V3), breakfast was to be eaten at home 2 h before the study product was taken (i.e., at 7 a.m.). To standardize food intake, volunteers were asked to eat two pastries or three slices of bread with butter and jam and to exclude tea, coffee, maté, or any energy drink.

At the study center, compliance with protocol was verified. Initial blood samples were collected at T-15 min to determine baseline. The PR or IR form was taken at 9 a.m. (T0). The monitor had to spray the IR form twice under the volunteer’s tongue, or the volunteer swallowed one tablet of the PR form with a glass of water. Blood samples were collected every 10 min from T0 to T60, every 30 min from T60 to T240, and then every 60 min from T240 to T420 or T540 (Fig. 1B). Blood pressure and heart rate were monitored throughout the course of the kinetics. Any intercurrent event, deviation from the protocol, concomitant treatment, or adverse event was recorded in case report form. A standardized snack (approximately 500 calories, identical for all kinetics and volunteers) was served at 2 p.m. (T300).

2.6 Biological Sample Preparation and Analysis

A maximum of 133 mL of blood (19 × 7 mL) was taken at each study visit and 10 mL at V1, corresponding to 276 mL for the whole study. Each blood sample was centrifuged at 4 °C. The plasma was decanted and separated into two aliquots, which were stored at –20 °C before treatment. One sample was used for melatonin assay and the other for 6-SMT assay. Melatonin and 6-SMT assays were performed by radioimmunoassay (RIA) using an anti-melatonin or anti-sulfatoxymelatonin antibody and radioactive tracers (labeled with iodine-125) [22]. Plasma melatonin and 6-SMT assays have been previously published, in particular antibody specificity and physiological validation [23, 24]. Assays are submitted to a permanent internal quality control. Briefly, for the melatonin assay, the detection limit is routinely 4 pg/mL. The intra- and inter-assay coefficients of variation are 9.5% and 12.5%, respectively, for a concentration of 50 pg/mL. For the 6-SMT assay, the detection limit is 4 pg/mL and the intra- and inter-assay coefficients of variation are 8% and 12%, respectively, for a concentration of 100 pg/mL. Samples from the same subject were processed in a single assay run to overcome the inter-assay variability of the technique. Quality controls were added to each series. Raw data processing (radioactivity counting) was performed using the Rialisme software.

2.7 Statistical Analyses

Twelve subjects were included in this study in accordance with some previous studies [25‐29]. To balance possible dropouts during the course of the study, incomplete kinetics, or unexploitable data, two additional subjects were included, leading to a total of 14 subjects.

The set of baseline parameters was described by counts and percentages for categorical variables, means, standard deviations, medians, and confidence intervals for quantitative variables. Since melatonin and its metabolite were present in the blood before supplementation, the AUC attributable to supplementation is an AUC from which the baseline (T-15 min) value was subtracted. Thus, it was possible to calculate not only the increase in the metabolite but also the percentage increase in AUC attributable to supplementation.

Data were recorded using the eNNOV Clinical system and analyzed using SAS software version 9.4. Mean C_max, T_max, T_1/2, and AUC values obtained for both forms were compared using a Wilcoxon signed-rank test for paired samples. The same test was used to compare mean melatonin and 6-SMT concentrations at each time point versus basal concentrations. The threshold for statistical significance was defined as alpha risk of 0.05.

The percentage of subjects who experienced at least one adverse event is presented. The frequency and nature of adverse events are presented for each form according to the imputability to the product, evolution, and therapeutic decision.

3 Results

3.1 Baseline Characteristics of Volunteers

Fourteen men were included in the study. Mean ± standard deviation (SD) age was 33.8 ± 8.3 years, ranging from 20 to 45 years. Mean BMI was 24.0 ± 0.8 kg/m² (median [range]: 24.3 [22.3–24.9] kg/m²), and blood parameters were within normal ranges. Volunteers had satisfactory quality of sleep (mean ± SD VAS score of 7.8 ± 0.7). In two volunteers, only one of the two kinetics was performed (the subjects did not come to the second study visit), therefore the pharmacokinetic parameters were obtained in 13 subjects for each galenic form, with no missing data for assays and calculations. Safety results are reported for the 14 volunteers.

3.2 Safety

Three out of 14 volunteers (21.4%) experienced one adverse event each. Two adverse events (strong sensation of thirst on returning home in the evening and headache) occurred in two volunteers within hours of the first kinetics with the PR form. One adverse event (nocturnal awakening) occurred in one volunteer within hours of the first kinetics with the IR form; there were no adverse events involving the oral sphere after administration of the spray. Imputability was considered unlikely by the investigator for nocturnal awakening and polydipsia. No serious adverse events occurred during or after the 26 kinetics.

3.3 Melatonin and 6-SMT Pharmacokinetics

The observed kinetics were consistent with those expected for prolonged and immediate-release forms (Fig. 2). For plasma melatonin, the ingestion of the PR form caused a progressive increase in concentrations, which was at the limit of significance at T10 (44.9 ± 68.8 pg/mL versus 4.6 ± 1.9 pg/mL at baseline, p = 0.057), then significant at the following times of sampling. C_max was reached on average 1 h after the intake (Fig. 2; Table 1). With the IR form, plasma melatonin levels were significantly increased as soon as 10 min after pulverization (1643 ± 966 pg/mL versus 7.0 ± 9.6 pg/mL at baseline, p < 0.0001). C_max was reached at T20, that is three times sooner than with the PR form (23.3 ± 6.5 min versus 64.2 ± 44.2 min, p < 0.001), and was twice as high as the C_max observed with the PR form (1151 ± 565 pg/mL versus 2332 ± 950 pg/mL, p < 0.001). Intersubject coefficients of variation calculated for each melatonin concentration following administration of the IR form were consistently lower than those for the PR form (data not shown), confirming the validity of the spray administration. Melatonin AUCs were 3070 and 2903 pg⋅h/mL for the PR and IR forms, respectively. Taking into consideration the doses, IR form bioavailability was nearly twice (1.89) as high as that of the PR form.

Table 1

Melatonin and 6-SMT pharmacokinetic parameters after administration of a unique dose of an immediate-release form (IR form; sublingual spray 1 mg) or a prolonged-release form (PR form; tablet 1.9 mg) in healthy volunteers

Parameter	PR form Mean ± SD	IR form Mean ± SD	p-Value
Plasma melatonin
C_max	1151 ± 565 pg/mL	2380 ± 950 pg/mL	< 0.001
T_max	64.2 ± 44.2 min	23.3 ± 6.5 min	< 0.001
T_1/2	133.3 ± 43.1 min	47.5 ± 19.6 min	< 0.001
AUC_0–540, AUC_0–420	3070 ± 1452 pg ⋅ h/mL	2903 ± 867 pg ⋅ h/mL	NS
Plasma 6-SMT
C_max	9395 ± 2894 pg/mL	12776 ± 3541 pg/mL	< 0.01
T_max	97.5 ± 40 min	36.7 ± 12.3 min	< 0.001
T_1/2	180 ± 69.7 min	63.3 ± 15.6 min	< 0.01
AUC_0–540, AUC_0–420	31967 ± 6554 pg⋅h/mL	18815 ± 4224 pg⋅h/mL	< 0.001

Mean values were compared by a Wilcoxon signed-rank test for paired samples. As each subject is its own control in this statistical test (paired test), the two volunteers who performed only one kinetics and had only one value were not included in the analysis. Therefore, the data and comparisons presented in this table include 12 volunteers

NS not significant

For plasma 6-SMT, C_max was reached on average 100 min after intake of the PR form, whereas with the IR form, C_max was reached three times sooner (97.5 ± 40 min versus 36.7 ± 12.3 min, p < 0.001; Table 1). The 6-SMT AUCs were 31967 ± 6554 pg⋅h/mL and 18815 ± 4224 pg⋅h/mL for the PR and IR form, respectively (p < 0.001).

The plasma melatonin AUC_0–540/420/plasma 6-SMT AUC_0–540/420 ratio was 0.09 for the PR form and 0.16 for the IR form, in agreement with a lower hepatic transformation with the IR form.

4 Discussion

In this crossover study, melatonin pharmacokinetic parameters and plasma 6-SMT levels were evaluated in healthy men aged 20-45 years who received a single dose of melatonin of 1.9 mg by taking a tablet (prolonged-release [PR] form) or 1 mg using a sublingual spray (immediate-release [IR] form). The results observed for melatonin and 6-SMT showed marked differences and were consistent with those expected for immediate- and prolonged-release forms. Pulverization of the sublingual spray resulted in an early, high peak of melatonin in blood, a profile consistent with an immediate-release form. In comparison, administration of the tablet produced a lower peak followed by a plasma melatonin plateau and a less rapid and more prolonged decay over time, a profile consistent with a prolonged-release form. At twice the dose, the peak concentration of plasma melatonin after ingestion of the tablet was half that after administration of the spray (1151 versus 2380 pg/mL on average), this peak being reached three times later with the tablet (60 versus 20 min on average). Up to 6 h after intake, the PR form released melatonin at a concentration with physiological meaning (i.e., more than 100 pg/mL, which corresponds to an average nocturnal peak concentration in young subjects). The intake of a usual dose of melatonin (i.e., 1–5 mg) usually generates, within 1 h after ingestion, melatonin concentrations that are 10–100 times the physiological nocturnal peak, with a return to basal concentrations in 4–8 h [30].

AUCs were of the same order of magnitude for both galenic forms (3070 ± 1452 pg⋅h/mL for PR form versus 2903 ± 867 pg⋅h/mL for IR form), whereas twice as much melatonin was present in the tablet as in the two sprays of the IR form (1.9 versus 1 mg). This observation suggests that melatonin is better absorbed after spraying the IR form, related to the sublingual absorption of this formulation. Indeed, absorption through oral mucosa avoids the first-pass effect associated with liver metabolism whereas it is established that only a small proportion of melatonin administered per os (~ 15%) reaches the systemic circulation [31]. The plasma melatonin AUC/plasma 6-SMT AUC ratios of 0.09 for the PR form and of 0.16 for the IR form are in line with this. However, relatively high 6-SMT levels were observed in plasma with the IR form. This could be the result of saturation of the transmucosal melatonin passage, leading to swallowing of the excess melatonin, which was finally submitted to the first hepatic metabolism.

It is difficult to compare the observed pharmacokinetic constants with those obtained in published studies since the profiles and parameters vary depending on the formulation, dose, route of administration, and population studied. However, the profiles observed in our study are in agreement with those reported in some previously published studies conducted with immediate- and prolonged-release forms [1, 13, 31, 32]. Especially, the profiles reported in our study for both galenic forms in adults aged between 20 and 45 years are close to those previously reported in adults aged over 55 years with a prolonged-release form and an immediate-release form, each containing 2 mg of melatonin [1, 19]. It was shown that the prolonged-release formulation containing 2 mg of melatonin resulted in a plasma peak 2.6 h after ingestion and levels were maintained for at least 3.5 h [33]. The order of magnitude of the pharmacokinetic constants with the prolonged-release and the immediate-release forms containing 2 mg of melatonin is similar to the constants reported in our study, although their measurements were performed in the elderly who are known to display a reduced metabolism (absorption of ingested melatonin reduced by up to 50% in the elderly [34]).

5 Conclusions

Overall, our results suggest that the galenic forms containing melatonin assessed in this study are suitable for the management of certain sleep disorders such as sleep onset delay and transient nocturnal awakenings for the IR form and insomnia for the PR form.

Acknowledgements

The authors thank CEN Nutriment for carrying out the statistical analyses.

Declarations

Funding

The study was funded by PiLeJe Laboratoire.

Conflict of interest

S. Ait Abdellah, C. Gal, I. Guinobert, V. Bardot, and C. Blondeau are employees of PiLeJe Laboratoire. B. Claustrat has been a consultant for PiLeJe, Biocodex, and Sanofi. V. Raverot declared that she has no conflicts of interest.

Ethical approval

The study received a favorable opinion from a Personal Protection Committee (CPP Sud-Est I, CHU Saint Etienne, France) before its implementation on 10 July 2020.

Availability of data and material

Data that support the findings of the study may be requested from the corresponding author.

Code availability

Not applicable.

Informed consent was obtained from all individual participants included in the study.

Not applicable.

Author contributions

Conceptualization: SAA, IG, BC; Methodology: SAA, IG, VB, CG, VR, BC; Formal analysis and investigation: SAA, IG, VB, CG, VR, BC; Writing—original draft preparation: CB; Writing—review and editing: CB, SAA, IG, VB, CG, VR, BC; Resources: CG, SAA; Supervision: CG, SAA. All authors read and approved the final manuscript.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Quera-Salva M-A, Claustrat B. Mélatonine: aspects physiologiques et pharmacologiques en relation avec le sommeil, intérêt d’une forme galénique à libération prolongée (Circadin^®) dans l’insomnie. Encéphale. 2018;44:548–57. https://doi.org/10.1016/j.encep.2018.06.005.CrossRefPubMed

Leone AM, Francis PL, Silman RE. The isolation, purification, and characterisation of the principal urinary metabolites of melatonin. J Pineal Res. 1987;4:253–66. https://doi.org/10.1111/j.1600-079x.1987.tb00863.x.CrossRefPubMed

Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with Atenolol*. J Clin Endocrinol Metab. 1985;60:1166–73. https://doi.org/10.1210/jcem-60-6-1166.CrossRefPubMed

Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27:87–98. https://doi.org/10.1185/03007995.2010.537317.CrossRef

Bartlett DJ, Biggs SN, Armstrong SM. Circadian rhythm disorders among adolescents: assessment and treatment options. Med J Aust. 2013;199:S16-20. https://doi.org/10.5694/mja13.10912.CrossRefPubMed

Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77:975–85. https://doi.org/10.1111/bcp.12294.CrossRefPubMed

Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–61. https://doi.org/10.2147/CIA.S65625.CrossRefPubMedPubMedCentral

Amstrup AK, Sikjaer T, Mosekilde L, Rejnmark L. The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial. Nutr J. 2015;14:102. https://doi.org/10.1186/s12937-015-0093-1.CrossRefPubMedPubMedCentral

Chang Y-S, Lin M-H, Lee J-H, Lee P-L, Dai Y-S, Chu K-H, et al. Melatonin supplementation for children with atopic dermatitis and sleep disturbance: a randomized clinical trial. JAMA Pediatr. 2016;170:35–42. https://doi.org/10.1001/jamapediatrics.2015.3092.CrossRefPubMed

10.

EFSA. Scientific opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFS2. 2011;9:2241. https://doi.org/10.2903/j.efsa.2011.2241.

11.

Lim S, Park S, Koyanagi A, Yang JW, Jacob L, Yon DK, et al. Effects of exogenous melatonin supplementation on health outcomes: an umbrella review of meta-analyses based on randomized controlled trials. Pharmacol Res. 2022;176: 106052. https://doi.org/10.1016/j.phrs.2021.106052.CrossRefPubMed

12.

Fatemeh G, Sajjad M, Niloufar R, Neda S, Leila S, Khadijeh M. Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2022;269:205–16. https://doi.org/10.1007/s00415-020-10381-w.CrossRefPubMed

13.

Biggio G, Biggio F, Talani G, Mostallino MC, Aguglia A, Aguglia E, Palagini L. Melatonin: from neurobiology to treatment. Brain Sci. 2021. https://doi.org/10.3390/brainsci11091121.CrossRefPubMedPubMedCentral

14.

Dumur J, Csajka C, Pavec O, Messaoudi S, Cretignier T, Gaspar F, Lang PO. Quelle alternative aux benzodiazépines, Z-pills et autres hypnotiques pour les personnes âgées ?: Mélatonine, valériane ou clométhiazole. Rev Med Suisse. 2018;14:2018–23. https://doi.org/10.53738/REVMED.2018.14.626.2018.CrossRefPubMed

15.

VIDAL. Mélatonine—Complément alimentaire—VIDAL. 06/01/2023. https://www.vidal.fr/parapharmacie/complements-alimentaires/melatonine.html. Accessed 6 Jan 2023.

16.

Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24. https://doi.org/10.1016/j.smrv.2004.08.001.CrossRefPubMed

17.

Harpsøe NG, Andersen LPH, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71:901–9. https://doi.org/10.1007/s00228-015-1873-4.CrossRefPubMed

18.

Román Martinez M, García Aguilar E, Martin Vílchez S, González García J, Luquero-Bueno S, Camargo-Mamani P, et al. Bioavailability of Oniria^®, a melatonin prolonged-release formulation, versus immediate-release melatonin in healthy volunteers. Drugs R D. 2022;22:235–43. https://doi.org/10.1007/s40268-022-00394-3.CrossRefPubMedPubMedCentral

19.

Monaca C, Taillard J, Claustrat B. Insomnie primaire du patient de plus de 55 ans: intérêt d’un nouvel hypnotique, Circadin^®: primary insomnia in patients over 55: the interest of a new hypnotic, Circadin^®. La Lettre du Pharmacologue. 2009;23:104–8.

20.

Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4:97–110.PubMed

21.

Olesen J. The international classification of headache disorders 2nd edition (ICHD-II). Rev Neurol (Paris). 2005;161:689–91. https://doi.org/10.1016/s0035-3787(05)85119-7.CrossRefPubMed

22.

Brun J, Chamba G, Khalfallah Y, Girard P, Boissy I, Bastuji H, et al. Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. J Sleep Res. 1998;7:105–14. https://doi.org/10.1046/j.1365-2869.1998.00100.x.CrossRefPubMed

23.

Brun J, Claustrat B, Harthé C, Vitte P, Cohen R, Chazot G. Melatonin RIA: analytical and physiological criteria of validity. In: Brown G, Wainwright S, editors. The pineal gland, endocrine aspects. Advances in the biosciences. Oxford: Pergamon Press; 1985. p. 41–5.

24.

Harthé C, Claustrat B, Brun J, Chazot G. Direct radioimmunoassay of 6-sulfatoxymelatonin in plasma with use of an iodinated tracer. Clin Chem. 1991;37:536–9.CrossRefPubMed

25.

Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48:142–7. https://doi.org/10.1111/j.1600-079X.2009.00737.x.CrossRefPubMed

26.

Härtter S, Nordmark A, Rose D-M, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003;56:679–82. https://doi.org/10.1046/j.1365-2125.2003.01933.x.CrossRefPubMedPubMedCentral

27.

Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol. 1985;19:517–21. https://doi.org/10.1111/j.1365-2125.1985.tb02679.x.CrossRefPubMedPubMedCentral

28.

Lopez-Gamboa M, Canales-Gomez JS, Sandoval TJC, Tovar EN, Meja MA, Palma-Aguirre J. Bioavailability of long acting capsules of melatonin in Mexican healthy volunteers. J Bioequiv Bioavailab. 2010;2:116–9. https://doi.org/10.4172/jbb.CrossRef

29.

DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40:781–4. https://doi.org/10.1177/00912700022009422.CrossRefPubMed

30.

Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C. Melatonin: pharmacology, functions and therapeutic benefits. CN. 2017;15:434–43. https://doi.org/10.2174/1570159X14666161228122115.CrossRef

31.

Bartoli A, De Gregori S, Molinaro M, Broglia M, Tinelli C, Imberti R. Bioavailability of a new oral spray melatonin emulsion compared with a standard oral formulation in healthy volunteers. J Bioequival Bioavailab. 2012;4:96–9. https://doi.org/10.4172/jbb.1000120.CrossRef

32.

Andersen LPH, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, Gögenur I. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016;17:8. https://doi.org/10.1186/s40360-016-0052-2.CrossRefPubMedPubMedCentral

33.

Palagini L, Manni R, Aguglia E, Amore M, Brugnoli R, Bioulac S, et al. International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Front Psychiatry. 2021;12: 688890. https://doi.org/10.3389/fpsyt.2021.688890.CrossRefPubMedPubMedCentral

34.

CHMP. Circadin, INN-melatonin. https://www.ema.europa.eu/en/documents/product-information/circadin-epar-product-information_en.pdf. Consulted on 30 May 2023.

Titel: Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
verfasst von: Samira Ait Abdellah
Véronique Raverot
Caroline Gal
Isabelle Guinobert
Valérie Bardot
Claude Blondeau
Bruno Claustrat
Publikationsdatum: 12.07.2023
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 3/2023
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-023-00431-9

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers

Abstract

Background

Objective

Methods

Results

Conclusions

Trial Registry

1 Introduction

2 Materials and Methods

2.1 Study Products

2.2 Study Design and Ethics Statement

2.3 Volunteers

2.4 Study Endpoints

2.5 Study Flow and Data Collection

2.6 Biological Sample Preparation and Analysis

2.7 Statistical Analyses

3 Results

3.1 Baseline Characteristics of Volunteers

3.2 Safety

3.3 Melatonin and 6-SMT Pharmacokinetics

4 Discussion

5 Conclusions

Acknowledgements

Declarations

Funding

Conflict of interest

Ethical approval

Availability of data and material

Code availability

Author contributions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Trial Registry

1 Introduction

2 Materials and Methods

2.1 Study Products

2.2 Study Design and Ethics Statement

2.3 Volunteers

2.4 Study Endpoints

2.5 Study Flow and Data Collection

2.6 Biological Sample Preparation and Analysis

2.7 Statistical Analyses

3 Results

3.1 Baseline Characteristics of Volunteers

3.2 Safety

3.3 Melatonin and 6-SMT Pharmacokinetics

4 Discussion

5 Conclusions

Acknowledgements

Declarations

Funding

Conflict of interest

Ethical approval

Availability of data and material

Code availability

Consent to participate

Consent for publication

Author contributions

Weitere Artikel der Ausgabe 3/2023

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis

Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo®] Obtained from a Manufacturing Process Preserving IgA/IgM Potential of Human Plasma

Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma